triple negative breast cancer tnbc market insight
DelveInsight's 'Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of TNBC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Triple Negative Breast Cancer (TNBC) from 2017 to 2028 segmented by G8 markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan
China
Study Period: 2017-2028
Triple Negative Breast Cancer (TNBC) - Disease Understanding and Treatment Algorithm
The DelveInsight Triple Negative Breast Cancer (TNBC) market report gives the thorough understanding of the Triple Negative Breast Cancer by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Triple Negative Breast Cancer in the US, Europe, Japan and China.
Triple Negative Breast Cancer Epidemiology
The Triple Negative Breast Cancer (TNBC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every G8 Countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed incident cases and sub-type specific incident cases) scenario of Triple Negative Breast Cancer (TNBC) in the G8 Countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2017-2028.
According to DelveInsight, the total number of diagnosed incident population of Triple Negative Breast Cancer (TNBC) was found to be 123,914 in the year 2017.
Triple Negative Breast Cancer Drug Chapters
This segment of the Triple Negative Breast Cancer report encloses the detailed analysis of marketed drugs and late stage (Registration, Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
At present, systemic chemotherapy remains the mainstay for the treatment of TNBC due to lack of targeted therapies and contributes towards the market size of TNBC. The several therapeutic classes of the drugs include DNA repair complex like (platinum compounds and taxanes), p53 like (taxanes), cell proliferation like (anthracycline containing regimen) and targeted therapy. Detailed chapter for upcoming therapies like Sacituzumab Govitecan (Immunomedics), Atezolizumab (Roche), Pembrolizumab (Merck), Ipatasertib (Roche), Enzalutamide (Pfizer/Astellas), Cobimetinib (Roche), Rucaparib (Clovis Oncology), Niraparib (Tesaro) and Capitasertib (AstraZeneca) have been covered in the report.
Triple Negative Breast Cancer Market Outlook
The Triple Negative Breast Cancer market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Triple Negative Breast Cancer in G8 Countries was found to be USD 0.543 billion in 2017, and is expected to increase at a CAGR of XX% from 2017-2028.
Triple Negative Breast Cancer Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Triple Negative Breast Cancer Report Insights
Patient Population
Therapeutic Approaches
Pipeline Analysis
Market Size and Trends
Market Opportunities
Impact of upcoming Therapies
Triple Negative Breast Cancer Report Key Strengths
10 Year Forecast
G8 Countries Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition
Triple Negative Breast Cancer Report Assessment
Current Treatment Practices
Unmet Needs
Detailed Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
Key Benefits
This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Triple Negative Breast Cancer market
Organize sales and marketing efforts by identifying the best opportunities for Triple Negative Breast Cancer market
To understand the future market competition in the Triple Negative Breast Cancer market